Evolution of translational omics : lessons learned and the path forward

Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detec...

Full description

Corporate Author: Institute of Medicine (U.S.) Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials
Other Authors: Micheel, Christine (Editor), Nass, Sharyl J. (Editor), Omenn, Gilbert S. (Editor)
Format: eBook
Language:English
Published: Washington, D.C. National Academies Press [2012], 2012
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02478nam a2200349 u 4500
001 EB000944329
003 EBX01000000000000000737919
005 00000000000000.0
007 tu|||||||||||||||||||||
008 150223 r ||| eng
020 |a 0309224187 
020 |a 9780309224185 
100 1 |a Micheel, Christine  |e [editor] 
245 0 0 |a Evolution of translational omics  |h Elektronische Ressource  |b lessons learned and the path forward  |c Christine M. Micheel, Sharyl J. Nass, Gilbert S. Omenn, editors ; Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Board on Health Care Services, Board on Health Sciences Policy, Institute of Medicine of the National Academies 
260 |a Washington, D.C.  |b National Academies Press  |c [2012], 2012 
300 |a 1 PDF file (xv, 338 pages  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Biotechnology 
653 |a Translational Medical Research 
653 |a Validation Studies as Topic 
653 |a Molecular Diagnostic Techniques 
653 |a Genomics 
700 1 |a Nass, Sharyl J.  |e [editor] 
700 1 |a Omenn, Gilbert S.  |e [editor] 
710 2 |a Institute of Medicine (U.S.)  |b Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
500 |a Title from PDF t.p 
856 |u https://www.ncbi.nlm.nih.gov/books/NBK202168  |3 Volltext 
082 0 |a 600 
520 |a Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials